Landmark Study Confirms GRAZAX(R) as the Only Grass Allergy Immunotherapy Tablet to Show Sustained Effect 2 Years After Treatment Completion

LONDON, June 7, 2010 - Data published at the European Allergy, Asthma & Clinical
Immunology (EAACI) congress in London today documents that GRAZAX(R) is the
only allergy immunotherapy tablet (AIT) to show sustained disease control 2
years after treatment completion. Leading specialists emphasise the relevance
of the data with regard to inclusion in guidelines for treatment of grass
pollen allergy.

Traditional symptomatic medications, such as antihistamine
tablets and nasal corticosteroid sprays, only treat the symptoms of grass
pollen rhinoconjunctivitis or 'hay fever'. GRAZAX(R) tablet immunotherapy
targets the underlying cause of the disease, leading to a long-term disease
modifying effect in patients previously uncontrolled on symptomatic
treatments.

"Two years after completion of treatment, we see that GRAZAX(R) reduced
hay fever symptoms with the same magnitude as in the previous year of the
clinical study. Completion of the GT-08 study brings us more evidence that
this efficacy is sustained during and two years after treatment with
GRAZAX(R)" highlights Professor Stephen R. Durham, the GT-08 study Lead
Investigator and Head of Section for Allergy and Clinical Immunology at the
National Heart & Lung Institute, Imperial College London and Professor of
Allergy and Respiratory Medicine at Royal Brompton Hospital London.

"Allergic rhinoconjunctivitis is a chronic disease with
increasing prevalence all over Europe. By 2015, every second person might be
suffering from at least one form of allergic disease" said Marianella
Salapatas, President of the European Federation of Allergy and Airways
Diseases Patients Association (EFA). "Symptoms can be very bothersome,
inevitably resulting in a reduced ability of the patients to actively
participate in social and professional life. Unfortunately, allergic rhinitis
is considered trivial and often mistaken for viral. This then may lead to
patients being under diagnosed and undertreated."

Discussion on treatment guidelines needed

The new data presented at EAACI represent a potential
breakthrough for the future management of grass-allergic rhinoconjunctivitis.
"A fact that we have to take into account for future treatment of
grass-allergic rhinoconjunctivitis patients" concluded Erkka Valovirta, Chief
Pediatrician and Pediatric Allergist, Allergy Center Turku, Finland. "It has
been acknowledged by European regulatory authorities that treatment with
GRAZAX(R) is disease-modifying. By that GRAZAX(R) fulfills the EMEA demands
for robust clinical data on Specific Immunotherapy in treating allergic
symptoms, showing long-term efficacy and sustained clinical effect during and
after treatment completion."

A landmark study has been completed, and the results confirm
that AIT for grass pollen induced rhinoconjunctivitis provides the treating
physician with the strongest levels of evidence presently available.

Background Information

About the GRAZAX(R) GT-08 study

The pivotal GRAZAX(R) GT-08 study is a randomized,
parallel-group, double-blind, placebo-controlled multicentre study. Patients
were randomised to receive either 3 years of GRAZAX(R) or placebo, followed
by a 2 year follow up period. Throughout the study all patients had free
access to symptomatic medications.

About GRAZAX(R)

GRAZAX(R) is a fast dissolving, once-daily allergy
immunotherapy tablet (AIT) that is suitable for home administration.

In 2006, GRAZAX(R) was the first AIT to be approved via the
European Mutual Recognition Process (MRP) in 27 countries. Subsequently,
GRAZAX(R) has been made available throughout Europe (Austria, Denmark,
Germany, Greece, Finland, Holland, Ireland, Italy, Norway, Sweden, Spain,
Switzerland and the United Kingdom).

In 2008 the GRAZAX(R) license indication was extended to
include the treatment of children and adolescents (5 - 17 years old) with
grass pollen allergic rhinoconjunctivitis. More recently, in September 2009,
GRAZAX(R) was approved as the first registered disease-modifying AIT for
grass pollen allergic rhinoconjunctivitis.

About ALK

ALK is a research-driven global pharmaceutical company
focusing on allergy treatment, prevention and diagnosis. Our mission is to
improve quality of life for people with allergies by developing
pharmaceutical products that target the actual cause of the condition. ALK is
a world leader in allergy immunotherapy - a unique treatment that induces a
protective immune response that reduces and potentially halts the allergic
reaction. Allergy immunotherapy is traditionally administered as subcutaneous
injections or sublingual droplets. Our aim is to extend the use of allergy
immunotherapy by introducing convenient, tablet-based options, thereby
offering many more patients a causal allergy treatment.

ALK has entered into a strategic partnership regarding the
tablet programme with Schering-Plough in North America. ALK has approximately
1,500 employees with subsidiaries, production facilities and distributors
worldwide. The company is headquartered in Horsholm, Denmark and listed on
NASDAQ OMX Copenhagen A/S. 'ALK' is an abbreviation of 'Allergological
Laboratory Copenhagen (Kobenhavn)'. Further information is available at
www.alk-abello.com and www.GRAZAX(R).com.

For further information, please contact: Journalists: Martin Barlebo, Director, ALK Group Communications, +45-20-6411-43. Analysts and investors: Per Plotnikof, Director ALK Investor Relations, +45-22-6125-25.